Cabaletta Bio (CABA) News Today

Cabaletta Bio, Inc. (NASDAQ:CABA) shares are moving today as investors weigh a series of clinical readouts, analyst updates and a dilutive capital raise. The stock’s recent decline reflects concerns over shareholder dilution from a $100 million public offering, offset in part by encouraging trial data and upgraded analyst sentiment.

• Promising Rese-cel safety and efficacy data to be presented at EULAR 2025, where 7 of 8 myositis patients achieved sustained, clinically meaningful responses
• RESET trial results reported strong transformative autoimmune therapy data, underscoring the potential of Cabaletta’s cell therapies
• Cantor Fitzgerald narrowed its FY 2026 loss estimate to ($0.95) per share versus a consensus of ($2.34), suggesting better-than-expected financial outlook
• HC Wainwright reiterated its “Buy” rating and set a $25.00 price target, implying more than 1,200% upside from current levels
• Announced and priced an underwritten offering to raise $100 million via 39.2 million shares and accompanying warrants at $2.00 per unit, with a 30-day option for 15 million additional shares
• Proposed offering proceeds earmarked to fund ongoing cell therapy development and advance multiple autoimmune programs
• Analysts note both sector headwinds and Cabaletta’s clear clinical direction, leaving the net impact on valuation mixed
• Shares slid over 28% after the public offering was priced, reflecting dilution concerns among existing stockholders
• Stock tumbled following the announcement and pricing of the $100 million securities offering